Healthcare Private Placement and M&A Transactions Review Week Ending September 15, 2024

Pantera: The company raised EUR 134 million of Series A venture funding on September 11, 2024, putting the company’s pre-money valuation at EUR 179.8 million. The company is an operator of a biotech business intended to offer large-scale production of actinium-225 (225Ac) to treat cancer patients.

Vignette Bio: The company raised $105 million of venture funding from Foresite Capital, Qiming Venture Partners and Samsara BioCapital on September 13, 2024. Mirae Asset Capital Life Science also participated in the round. The company is a developer of therapies designed to address immunology and inflammation associated diseases.

F2G: The company raised $100 million of venture funding in a deal led by AMR Action Fund and Intermediate Capital Group on September 12, 2024. Brace Pharma Capital, Johnson & Johnson, Pfizer, Merifin Capital, Advent Life Sciences, Morningside Group, Forbion, Sofinnova Partners, Novo Holdings and Blue Owl Capital also participated in the round. The company is a developer of a biotech drug designed to treat novel therapies for life-threatening fungal infections.

Inflammatix: The company raised $57 million of Series E venture funding in a deal led by Khosla Ventures and Think.Health on September 12, 2024. OSF Healthcare, Iberis Capital, Raw Ventures, Vesalius Biocapital Partners, Northpond Ventures, D1 Capital Partners and other undisclosed investors also participated in the round. The company is a developer of molecular diagnostics tests designed to read the immune system to resolve major clinical and public health challenges.

Epsilogen: The company raised GBP 43.3 million of Series B venture funding from Novartis Venture Fund, British Patient Capital, and Schroders Capital on September 9, 2024. Caribou Property, 3B Future Health Fund, ALSA Ventures, and Epidarex Capital also participated in the round. The company is a biopharmaceutical business developing immunoglobulin E (IgE) antibodies to treat cancer .

SpectraWAVE: The company raised $49.3 million in Series B venture funding in a deal led by Johnson & Johnson Innovation – JJDC on September 11, 2024, putting the company’s pre-money valuation at $50.7 million. Nova Ventures Group, Deerfield Management, Lumira Ventures, S3 Ventures, SV Health Investors and Minogue Consulting also participated in the round. The company is a developer of an intravascular imaging technology designed to improve coronary artery disease outcomes with photonics.

CorFlow: The company raised EUR 44 million of Series B venture funding in a deal led by Broadview Ventures and Panakes Partners on September 10, 2024. M&L Investments, KOFA Healthcare, Mérieux Equity Partners, Unorthodox Ventures, 415 Capital, Valiance, Wellington Partners, Monte Carlo Capital, Korys Investments and Laerdal Million Lives Fund also participated in the round. The company is a developer of a diagnostic and therapeutic medical device designed to improve microvascular obstructions after a heart attack.

Radiant Biotherapeutics: The company raised $35 million of Series A venture funding in a deal led by Amplitude Ventures and Bill & Melinda Gates Foundation on September 11, 2024. BDC Capital, FACIT, Alexandria Venture Investments, Toronto Innovation Acceleration Partners and Abrdn also participated in the round. The company is a developer of a modular multi-valent and multi-specific platform designed for antibody engineering.

XP Health: The company raised $32 million of Series B venture funding in a deal led by QED Investors on September 12, 2024. American Family Ventures, Valor Capital Group, HC9 Ventures, ManchesterStory, and Canvas Ventures also participated in the round. The company is a developer of an artificial intelligence-powered vision benefits platform designed to work alongside traditional insurance to boost utilization and expand eyecare.

Pieces: The company raised $25 million of venture funding from Children’s Medical Center of Dallas, OSF Ventures and Concord Health Partners on September 10, 2024. Rittenhouse Ventures also participated in the round. The company is a developer of a generative AI technology designed to assess and connect patients and healthcare systems.

Catalyst OrthoScience: The company raised $20 million of venture funding in a combination of debt and equity from Bridge Bank, RC Capital and Mutual Capital Partners on September 10, 2024. The company is a developer of a shoulder replacement system designed to make orthopedic surgery less invasive and more efficient.

NanoSyrinx: The company raised GBP 10 million of venture funding in a deal led by M Ventures, BGF and Octopus Ventures on September 10, 2024. Eli Lilly and Company, IQ Capital Partners and Meltwind Advisory also participated in the round. The company is a developer of a novel intracellular drug delivery system for biological molecules.

Pulmotect: The company raised $5.9 million of Series C financing from Fannin Partners with participation from Axil Capital on September 9, 2024. The company is a developer of a respiratory therapeutics technology intended to reduce morbidity and mortality in patients at risk of severe respiratory diseases.

GenEp: The company raised $4 million of venture funding from undisclosed investors on September 10, 2024. The company is an operator of a biotechnological business intended to create therapies targeting mutations of sodium and other ion channels to address rare genetic epilepsies.

Syantra: The company raised CAD 4.9 million of Series A1 venture funding from undisclosed investors on September 11, 2024. The company is a developer of precision healthcare screening tools and devices designed for early detection and diagnosis of cancer.

Huma.AI: The company raised $2 million of venture funding from undisclosed investors on September 13, 2024. The company is a developer of an artificial intelligence-powered business development platform intended to automate healthcare.

Distalmotion: The company raised an undisclosed amount of venture funding in a deal led by Revival Healthcare Capital on September 13, 2024. Helvetica Capital and Swiss Entrepreneurs Foundation also participated in the round. The company is a developer of a surgical robotic technology.

Paragonix / Getinge: The company was acquired by Getinge, a subsidiary of Carl Bennet, for $253 million on September 11, 2024. The company is a developer of organ transportation devices.

Ad-Tech Medical Instrument / Nihon Kohden: The company was acquired by Nihon Kohden for an undisclosed amount on September 12, 2024. The company is a manufacturer of intra-cranial monitoring devices designed to treat intractable epilepsy as well as complimentary neurosurgical instrumentation.

NeuroAdvanced / Nihon Kohden: The company reached a definitive agreement to be acquired by Nihon Kohden for JPY 16 billion on September 12, 2024. The company is a developer and manufacturer of biphasic AEDs and defibrillators for hospital and ambulance use.

Clinigence Health / AssureCare: The company was acquired by AssureCare for an undisclosed amount on September 13, 2024. The company is a developer of population health management tools for healthcare organizations.

eClinical Solutions / GI Partners: The company entered into a definitive agreement to be acquired by GI Partners through an LBO on September 12, 2024 for an undisclosed amount. The company is a developer of a biometrics data and analytics platform.

Gentronix / Scantox: The company was acquired by Scantox, via its financial sponsor Impilo, through an LBO on September 9, 2024 for an undisclosed amount. The company is an operator of a specialist contract research organization and provides genetic toxicology services to the global pharma, biotech, and agrichem industries.

GlucoGuard / Universal Wellness Holding: The company was acquired by Universal Wellness Holding for an undisclosed amount on September 9, 2024. The company is an operator of an artificial intelligence platform intended to monitor an innovative solution for managing nocturnal Hypoglycemia.

Medibase / CellSource Co: The company was acquired by CellSource Co for an undisclosed amount on September 12, 2024. The company is a developer of medical records software for medical clinics.

Mirador Global / Citrus Health Group: The company, a subsidiary of COEUS, was acquired by Citrus Health Group, via its financial sponsors NaviMed Capital and Five Points Capital, through an LBO on September 9, 2024 for an undisclosed amount. The company is a provider of drug commercialization assessment and launch planning services located in Kennett Square, Pennsylvania.

Noir Medical Supplies / CYIOS: The company was acquired by CYIOS for an undisclosed amount on September 11, 2024. The company is a distributor of over the counter medical supplies for the healthcare industry.

PharmaForceIQ / Eir Partners: The company was acquired by Eir Partners through an LBO on September 10, 2024 for an undisclosed amount. The company is a provider of AI-powered omnichannel marketing solutions for the life sciences industry.

Vignette Bio / Candid Therapeutics: The company was acquired by Candid Therapeutics for an undisclosed amount on September 9, 2024. The company is a developer of therapies designed to address immunology and inflammation associated diseases.